Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. (Q40960309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

2

D R Matthews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

G Fulcher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

V Perkovic

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

D de Zeeuw

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

K W Mahaffey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

C Mathieu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

V Woo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

C Wysham

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

G Capuano

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

M Desai

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

W Shaw

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

F Vercruysse

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

G Meininger

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

CANVAS trial collaborative group

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

8 December 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

26 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

82-91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

26 February 2020

cites work

1 reference

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

21 January 2018

1 reference

Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.

21 January 2018

1 reference

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

21 January 2018

1 reference

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial

21 January 2018

1 reference

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12589

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26450639%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference